Mantle Cell Lymphoma
Expert Perspective
Emerging Treatment Options for Mantle Cell Lymphoma
Expert Perspective
The Evolving Role for Transplantation in Mantle Cell Lymphoma
News
FDA approves pirtobrutinib for r/r mantle cell lymphoma
Pirtobrutinib for relapsed or refractory mantle cell lymphoma has been approved by the Food and Drug Administration.
News
MCL: Event-free survival at 2 years bodes well
With current therapies, patients who achieve 24 months of event-free survival live almost as long as the general population.
Conference Coverage
MCL: Ibrutinib could become the ‘new standard’
New research showed ibrutinib outperformed HSCT for treating younger patients with mantle cell lymphoma.
Conference Coverage
ASH 2022: New clinical data challenge long-held assumptions
Fresh research to be unveiled at the 2022 American Society of Hematology conference seems to overturn conventional wisdom across a range of issues...
Roundtable Discussion
Mantle Cell Lymphoma Roundtable Discussion
News
High cost and demand for old cancer drug sparks crisis
Experts have voiced alarm at the scarcity and cost of fludarabine, an old drug deemed crucial to cellular therapy for leukemia.
News
Transplant provides no clear survival benefit in real-world MCL study
The findings apparently contradict the survival benefit seen in clinical trial data, authors said, but are consistent with other recent...
News
Blame MCL, not transplantation, for late effects?
In patients with mantle cell lymphoma, long-term complications appeared to be caused by the disease itself, not by intensive therapy.
News
Phase 3 trial yields better way to predict MCL outcomes
In a phase 3 trial of mantle cell lymphoma outcomes, repeated evaluations of minimal residual disease over time improved prognostic power.